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Purpose or Objective: To synthesize and compare available 
evidence to compare the Long-Term clinical outcomes of 
proton therapy (PT) with those of carbon ion therapy (CIT) 
for stage I non-small cell lung cancer (NSCLC). 
 
Material and Methods: Clinical trials were searched for in 
Cochrane Library, PubMed, EMBASE,Web of Science and 
Chinese Biomedical Literature Database through Dec 2014. 
Additional articles were identified from searching 
bibliographies of retrieved articles. Two reviewers 
independently selected studies and extract data. Outcomes 
were analyzed by random-effects model meta-analysis and 
reported as odds ratio (OR) with 95% confidence intervals 
(CI). The meta-analysis was conducted with STATA 12.0 
software. 
 
Results: Three retrospective studies were included, the meta 
analysis showed that there were no difference between 
proton therapy and carbon ion radiotherapy for stage I non-
small cell lung cancer in the one year progression-free 
survival(PFS) was OR=1.13(95%CI:0.71,1.79), two years PFS 
was OR=1.25(95%CI:076,2.06),three years PFS was 
OR=1.02(95%CI:0.58,1.79),four years PFS was 
OR=0.73(95%CI:0.36,1.46),five years PFS was 
OR=0.50(95%CI:0.19,1.30), the one year overall survival(OS) 
was OR=1.01(95%CI:0.65,1.55),two years OS was 
OR=0.93(95%CI:0.59,1.46),three years OS was 
OR=0.94(95%CI:0.62,1.41) and four years OS was 
OR=0.65(95%CI:0.36,1.19),but there was difference in five 




Conclusion: Our data suggest that the clinical outcomes of 
stage I NSCLC patients treated with PT and CIT may be 
similar. PT may improve 5-year OS compared with CIT. 
However, no firm conclusion concerning the difference in 
clinical outcomes between these two partical therapies can 
be made because of the limitations of retrospective studies; 
more homogeneous prospective data, large multicentric and 
randomized trials are needed to compare the efficacy of PT 
with CIT for stage I NSCLC. 
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Purpose or Objective: Lung and esophageal cancer are 
characterized by aggressiveness and comprehend the 
majority of thorax malignancies. In both pathologies, the 
possibility to stratify patients (pts), early during radiotherapy 
(RT) or chemoradiotherapy (CRT) with interim 18F-FDG-
PET/CT (FDGint) is extremely appealing to optimize 
treatments. CRT-responding pts could benefit from further 
preoperative treatment, while non responding pts should 
discontinue CRT, to avoid toxicity, and not to delay surgery. 
Although controversial findings have been reported on the 
early value of FDGint in thorax cancer, some notable results 
support therapeutic decision based on its analysis. Reviews 
specifically addressing FDGint in thorax cancer are lacking. 
The purpose of this study is to evaluate where and whether 
FDGint may offer predictive and prognostic potentials. 
 
Material and Methods: A comprehensive review of the last 
decade literature was made, assembling studies on FDGint in 
pts affected by lung or esophageal malignances. Six different 
searches were completed on PubMed using keywords 
combined by Boolean operators (and, or). Studies inherent to 
FDGint for adaptive RT (aRT) were also included. Restrictions 
were: papers in English; 3D hybrid PET/CT studies; original 
papers only. Cross-references of the studies selected were 
also manually checked to complete the literature pursuit. 
 
Results: 1121 items in lung cancer and 193 in esophageal 
cancer were found. After the steps of process selection, 17 
studies were extracted for lung cancer (5 related to change 
of FDG uptake, 9 correlation with response and prognosis, 3 
aRT) reporting on 488 pts, and 8 studies for esophageal 
cancer (7 correlation with response and prognosis, 1 aRT) 
reporting on 318 pts. The main metabolic parameters 
correlated with outcomes, progression free survival, 
locoregional control, overall survival were the standardized 
uptake value, metabolic tumor volume, total lesion glycolysis 
and their variations. Lung studies did not give special 
emphasis to statistical analysis, while 6/8 esophageal studies 
reported the results of statistical ROC analysis (Figure). 
Among the 17 lung studies, 14 advocated the predictivity of 
FDGint, 3 showed the improvements by aRT. Among the 8 
esophageal studies, 4 sustained predictivity, 3 did not find 




Conclusion: Despite heterogeneity, the studies comprised in 
this review denoted FDGint as promising and challenging 
tracer for early assessment of outcomes during CRT. In lung 
cancer papers, all the authors sustain the predictivity of 
response and prognosis of FDGint. In esophageal cancer 
instead, its predictive and prognostic value cannot be 
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definitively established due to some controversial findings, 
the possible reasons of which demand further research with 
prospective and uniform protocols and analysis, great number 
of pts and adequate follow-up period. 
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Purpose or Objective: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. 
 
Material and Methods: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. Methods: 
A comprehensive search was conducted in the Cochrane 
Library, PubMed, EMBASE,Web of Science and Chinese 
Biomedical Literature Database (from inception to Feb 2015). 
Selection of studies, and extracting data were performed by 
two reviewers independently. Outcomes were analyzed by 
random-effects model meta-analysis and reported as odds 
ratio (OR) with 95% confidence intervals (CI). The meta-
analysis was conducted with STATA 12.0 software. 
 
Results: Eight trials(369 patients) were included, the meta 
analysis showed that the one year local control rate(LCR) was 
OR=0.89(95%CI:0.81,0.90),two years LCR was 
OR=0.81(95%CI:0.72,0.89),three years LCR was 
OR=0.64(95%CI:0.55,0.73),four years LCR was 
OR=0.23(95%CI:0.13,0.33) and five years LCR was 
OR=0.70(95%CI:0.67,0.73).the one year overall survival(OS) 
was OR=0.94(95%CI:0.88,0.99),two years OS was 
OR=0.85(95%CI:0.70,1.00),three years OS was 
OR=0.64(95%CI:0.50,0.78), four years OS was 
OR=0.29(95%CI:0.18,0.40) and five years OS was 
OR=0.34(95%CI:0.19,0.49).the one year progression-free 
survival(PFS) was OR=0.79(95%CI:0.69,0.89), two years PFS 
was OR=0.63(95%CI:0.52,0.75),three years PFS was 
OR=0.39(95%CI:0.28,0.51),four years PFS was 
OR=0.20(95%CI:0.10,0.29) and five years PFS was 
OR=0.08(95%CI:0.02,0.15).the recurrence was 
OR=0.46(95%CI:0.39,0.53) and distant metastasis was 
OR=0.20(95%CI:0.14,0.26). 
 
Conclusion: Carbon beam radiotherapy, which is an excellent 
new modality in terms of a high local control and survival, 
may be a valid alternative to surgery for Stage I cancer, 
especially for elderly and inoperable patients. 
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Purpose or Objective: Stereotactic ablative radiotherapy is 
an emerging non-invasive technique for the treatment of lung 
lesions. Both primary lesions and metastases may benefit 
from this approach, even in patients with low respiratory 
reserve. This work describes and evaluates institutional 
experience of SABR in lung location. 
 
Material and Methods: From May´12 to November´14, 82 
lesions in 67 patients were irradiated. 57 lesion were primary 
lung tumors and 25 metastases. Immobilization systems used 
in each patient was abdominal compressor and vacuum 
cushion o head-and-shoulders mask. An ITV was defined using 
three CT scans in three different phases of the respiratory 
cycle or with 4D RPM-Varian® system. The PTV was obtained 
by uniformly 5 mm ITV expanding. BED prescription was 
always over 100 Gy10 in 3-8 fractions following a risk-adapted 
protocol. 8 patient treatments were performed on a Clinac 
iXTM and 74 treatments on a TruebeamTM with high 
definition MLC. Volumetric modulated arc therapy 
(RapidArcTM) was mostly used, and image-guided RT was 
performed with cone-beam CT (CBCT). Intra-fraction 
movement was controlled by post-treatment CBCT and infra-
red ExacTrac. 
 
Results: Median age was 75y.o.(44-89). The median GTV/PTV 
size was 3.2/27.15cm3 (0.2-129.9/5.90-263.90). Intra-
fraction movement in all cases was less than 5mm according 
to post-treatment CBCT. At a median follow-up of 7(1-30) 
months, overall l local control was 92.7%, 89.5% for primary 
lesions and 100% for metastases. Mean overall survival was 18 
months for primary lesion (14.7-21.33 [95%]). No toxicities 
over G3 have been collected. 
 
Conclusion: VMAT based ablative radiotherapy achieves 
excellent control rates in both primary lesions and 
metastases. Overall survival also depends on specific 
characteristics of the patient. 
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Purpose or Objective: Receiving Radio(chemo)therapy 
[R(C)T] for pulmonary tumors some patients have or develop 
necrosis or fistulae (N/F) within the area of the treated 
tumor. Partially such N/F result in fatal complications like 
mediastinitis or pneumonia whereas other affected patients 
achieve good local control rates with long term survival after 
R(C)T. By retrospectively analyzing such cases we are aiming 
at identifying factors that might have an impact on the 
course of disease and should pre-therapeutically be 
considered in future. 
 
Material and Methods: Retrospective analysis of patients 
coming up with N/F in temporal association with chest RT 
applied at the University Medical Center Freiburg from 2006 
to 2013. Clinical and radiation parameters have been 
evaluated, acute and late toxicity, complications, clinical 
and imaging follow up have been assessed and will be 
analyzed with respect to local control and overall survival. 
 
Results: We identified 40 patients irradiated for pulmonary 
malignancies (mainly centrally located NSCLC, UICC IIIB/IV; 
16 female, 24 male; median age 64 years; 15 squamous cell-, 
15 adenocarcinoma, 10 other) who developed N/F in 
temporal association with chest RT. Intention of treatment 
was curative in 31 and palliative in 9 patients. 25 patients 
received R(C)T, 15 received RT alone with a median total 
dose of 54 Gy (14-72Gy). 26 patients revealed a necrotic 
primary tumor, 6 additionally necrotic lymph node 
metastases (LNM), 8 necrotic LNM, exclusively. In 34 lesions 
necrosis was found previous to RT, in 3 cases it occurred 
during, in 3 cases after RT.14 patients showed fistulae, all 
fistulae with esophageal or mediastinal involvement emerged 
after RT. For 16 patients G3, for 6 G4 toxicities have been 
reported, one patient died in consequence of an esophago-
tracheal fistula. All patients with N/F-connection to the 
esophagus revealed toxicities ≥G3, whereas some patients 
with centrally necrotic tumor and fistula without esophageal 
involvement revealed excellent long term follow ups. Median 
survival was 12,6 months (median FU 6,9 months). All 
patients with esophago-tracheal fistula died before reaching 
the median. Histology and location of the necrotic lesions 
didn’t show any significant impact on survival. 
 
Conclusion: R(C)T of pulmonary malignancies for patients 
with N/ F can be associated with high toxicity. One essential 
factor with impact on the clinical course seems to be the 
